APA (7th ed.) Citation

Dent, R., Cortés, J., Park, Y. H., Muñoz-Couselo, E., Kim, S., Sohn, J., . . . Schmid, P. Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: Exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study. BMC.

Chicago Style (17th ed.) Citation

Dent, Rebecca, et al. Molecular Determinants of Response to Neoadjuvant Pembrolizumab Plus Chemotherapy in Patients with High-risk, Early-stage, Triple-negative Breast Cancer: Exploratory Analysis of the Open-label, Multicohort Phase 1b KEYNOTE-173 Study. BMC.

MLA (9th ed.) Citation

Dent, Rebecca, et al. Molecular Determinants of Response to Neoadjuvant Pembrolizumab Plus Chemotherapy in Patients with High-risk, Early-stage, Triple-negative Breast Cancer: Exploratory Analysis of the Open-label, Multicohort Phase 1b KEYNOTE-173 Study. BMC.